Anti-Human MET/c-Met/HGFR Antibody (224G11) (HY196207)

Datasheet Compartir producto Copiar información

Precio(USD): $

Especificación:

50ug
100ug

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet

Vista general

Número de catálogo	HY196207
Descripción	Anti-Human MET/c-Met/HGFR Antibody (224G11) [224G11] (HY196207) is a human monoclonal antibody detecting MET in FCM. Suitable for Human. Highlights ●Flow Cytometry — Validated for flow cytometry applications.
Reactividad de especies	Human
Aplicaciones	FCM
Especie huésped	Human
Isotipo	IgG1, kappa
ID de clon	224G11
Clonalidad	Monoclonal
Objetivo	Tyrosine-protein kinase Met, Hepatocyte growth factor receptor, Proto-oncogene c-Met, Scatter factor receptor, HGF receptor, SF receptor, HGF/SF receptor, MET
Nivel de endotoxinas	Please contact with the lab for this information.
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P08581
Forma	Liquid
Buffer de almacenamiento	0.01M PBS, pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Fondo	Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
Nota	For research use only.

Imágenes

Flow Cytometry

Flow-cytometry using anti-human c-Met antibody.HeLa cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human c-Met antibody monoclonal antibody (Catalog # HY196207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.
Flow Cytometry

Flow-cytometry using anti-human c-Met antibody.HepG2 cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human c-Met antibody monoclonal antibody (Catalog # HY196207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.
Flow Cytometry

Flow-cytometry using anti-human c-Met antibody.HT-29 cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human c-Met antibody monoclonal antibody (Catalog # HY196207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.